Connect your AI

Cytokinetics CYTK Change in Inventories

Change in Inventories at other companies

Bristol-Myers SquibbBMY

-$14M-108%

Eli LillyLLY

$1.17B+86.3%

Merck & Co.MRK

$295M+41.3%

BioMarin PharmaceuticalsBMRN

-$44.49M-283%

Corcept TherapeuticsCORT

$3.27M+641%

MedtronicMDT

$131M-34.5%

Other financials

Income statement

Revenue$19.4M+1,126%

Operating income-$183.6M-18.0%

Net income-$206.0M-27.7%

EPS (diluted)-$1.67-22.8%

Balance sheet

Cash & equivalents$129.8M+76.2%

Total debt$418.2M+75.8%

Total equity-$826.6M-210%

Total assets$1.3B+0.7%

Cash flow

Operating cash flow-$145.5M-10.5%

CapEx$5.9M+4.7%

Free cash flow-$151.4M-10.3%

Valuation

Market cap$10.7B+70.6%

Enterprise value$10.98B+70.7%

P/S101.1×-225×

Profitability

Operating margin-605.1%-268pp

Net margin-784%-337pp

FCF margin-518.8%-223pp

Returns & leverage

Return on equity-337.6%—

Debt / equity2.2×—

Current ratio4.2×-1.8×

Where this comes from

Reported directly by Cytokinetics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInInventories.

The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cytokinetics's change in inventories.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Cytokinetics's change in inventories?: Cytokinetics (CYTK) reported change in inventories of $3.57M in Q1 2026.